Cascade Chemistry to produce API for COVID-19 trial

By Jenni Spinner contact

- Last updated on GMT

(Irina Shibanova/iStock via Getty Images Plus)
(Irina Shibanova/iStock via Getty Images Plus)

Related tags: API, Manufacturing, Clinical trial, COVID-19, Coronavirus

Tapped by Renibus Therapeutics, the CDMO will produce the API for clinical trials of investigational drug RBT-9 for an upcoming COVID-19 study.

Cascade Chemistry, a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, will produce the active pharmaceutical ingredient (API) for RBT-9 on behalf of client Renibus Therapeutics. The investigational therapy is entering a Phase II trial for COVID-19 patients at high risk due to age or comorbid conditions (such as kidney or cardiovascular disease).

RBT-9 is being developed by Renibus Therapeutics as an antiviral treatment with organ-protective attributes. The drug, recently awarded fast track designation by the US Food and Drug Administration (FDA) reportedly has demonstrated antiviral properties as well as immune-modulating activities in preclinical studies.

At the onset of the COVID-19 pandemic, Renibus Therapeutics reportedly worked quickly to plan and initiate an RVT-9 trial for COVID-19 patients. According to Cascade Chemistry, Renibus chose its production partner based on experience, flexibility and service focus.

Alvaro Guillem, CEO of Renibus Therapeutics, said Cascade Chemistry offered the knowledge and capabilities necessary to orchestrate and implement an effective strategy.

Cascade’s ability to move quickly to design, implement, and scale-up a comprehensive RBT-9 API manufacturing strategy has been one of the essential elements in our campaign to initiate clinical trials with minimal delay​,” Guillem said. “The professionalism, expertise, flexibility, and client commitment of the Cascade team have facilitated our collaborative effort to advance effective therapies for this devastating global pandemic​."

Jeremiah Marsden, Cascade Chemistry president, added that his company was eager for the opportunity to partner with Renibus to produce the necessary API to accelerate RBT-9 into clinical trials for the virus.

Our reputation as a reliable, experienced, and flexible outsourcing partner with exceptional chemistry problem-solving expertise is based on our many past successes with Renibus and other clients. These qualities are serving us well as we work to complete this important project with impeccable quality and all possible speed​,” Marsden said.

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars